Novel Macrolide and Ketolide Antibiotic Intermediates

Information

  • Research Project
  • 6582821
  • ApplicationId
    6582821
  • Core Project Number
    R43AI053926
  • Full Project Number
    1R43AI053926-01
  • Serial Number
    53926
  • FOA Number
  • Sub Project Id
  • Project Start Date
    5/1/2003 - 21 years ago
  • Project End Date
    4/30/2004 - 20 years ago
  • Program Officer Name
    JONES, WARREN
  • Budget Start Date
    5/1/2003 - 21 years ago
  • Budget End Date
    4/30/2004 - 20 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    -
Organizations

Novel Macrolide and Ketolide Antibiotic Intermediates

DESCRIPTION (provided by applicant): The objective of the proposed study is to generate novel macrolide and ketolide structures that may be useful as antibiotics themselves, or as chemical intermediates in the generation of new semi-synthetic antibiotics. Macrolides are effective in the treatment of respirtory infections. The new ketolide derivatives are particularly effective against an emerging public health threat, MLSB resistance (virginiamycin-, tylosin-, streptogramins-, and erythromycin-resistant) Streptococcus. pneumoniae. The new structures will be generated by molecular biotailoring, which is an environmentally low-impact fermentation process, as opposed to chemical synthesis. The project will involve eight biotailoring enzymes, and five macrolide- or ketolide-producing bactieral host strains, in novel combinatorial arrays to create structures that have never before been produced or tested for antibiotic activity. The biotailoring enzymes have been chosen based on analogous structure-activity relationships that show them to impart biological activity to the parent molecule. In addition, a new macrolide biosynthetic gene cluster will be cloned and its gene sequenced obtained in part, to identify new biotailoring enzymes for future work in Phase II.

IC Name
NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
  • Activity
    R43
  • Administering IC
    AI
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    265404
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    856
  • Ed Inst. Type
  • Funding ICs
    NIAID:265404\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    FERMALOGIC, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    CHICAGO
  • Organization State
    IL
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    60612
  • Organization District
    UNITED STATES